文献速递临床微生物分子诊断质量管理与危急值

住院成人艰难梭菌PCR阳性/毒素阴性治疗与未治疗的临床结局:准实验非劣效性研究

Clinical Outcomes of Treated and Untreated C. difficile PCR-Positive/Toxin-Negative Adult Hospitalized Patients: a Quasi-Experimental Noninferiority Study.
PubMed 文献 · J Clin Microbiol · 2022-05-25

该单中心准实验非劣效性研究比较了PCR阳性/毒素阴性住院患者仅报告PCR结果(多数治疗)与仅报告毒素结果(多数不治疗)的临床结局。共分析663份检测结果(632人,中位年龄61岁,50.4%免疫抑制)。8周症状性毒素转化和住院时长未达到预设非劣效阈值,而7天腹泻未缓解和30天全因死亡率相似且达到非劣效。数据支持对部分疑似CDI但毒素阴性的住院患者安全地不使用抗生素。

要点

  • PCR阳性/毒素阴性住院患者中,不治疗策略在7天腹泻未缓解和30天死亡率上非劣于治疗策略。
  • 8周症状性毒素转化和住院时长未达到非劣效阈值,提示不治疗需谨慎选择患者。
  • 干预组仅15.1%接受CDI治疗,前干预组91.5%接受治疗(P<0.001)。

核心结论

  • 对部分疑似CDI但毒素阴性的住院患者,不给予抗生素是安全的。

研究设计与样本

  • 单中心三级学术医院的准实验非劣效性研究,比较仅报告PCR结果(多数治疗)与仅报告CT-毒素结果(多数不治疗)的临床结局。
  • 共分析663份PCR阳性/CT-毒素阴性检测结果,来自632人,中位年龄61岁(IQR 44-72),50.4%免疫抑制。

主要发现

  • 前干预组接受CDI治疗的比例为91.5%,干预组为15.1%(P<0.001)。
  • 8周症状性毒素转化和住院时长未达到预设非劣效阈值。
  • 7天腹泻未缓解率:20.0% vs 13.7%(aOR 0.57,90%CI 0.32-1.01,P=0.1),达到非劣效。
  • 30天全因死亡率:8.6% vs 6.5%(aOR 0.46,90%CI 0.20-1.04,P=0.12),达到非劣效。

关键数值与推荐

  • 主要结局为8周症状性PCR阳性/CT-毒素阳性转化。
  • 次要结局包括7天腹泻缓解、住院时长和30天全因死亡率。

临床怎么用

  • 对选择性住院患者(疑似CDI但毒素阴性),可考虑不给予抗生素治疗。
  • 需结合临床评估选择合适患者,避免对所有PCR阳性/毒素阴性者常规治疗。

局限性

  • 准实验设计非随机对照,可能存在混杂。
  • 单中心研究,结果外推需谨慎。
  • 8周毒素转化和住院时长未达非劣效阈值,提示不治疗策略在某些结局上可能不劣于治疗未确立。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clostridioides difficile infection (CDI) is routinely diagnosed by PCR, with or without toxin enzyme immunoassay testing. The role of therapy for positive PCR and negative toxin remains unclear. The objective of this study was to determine whether clinical outcomes of PCR+/cycle threshold-based toxin (CT-toxin)- individuals vary by result reporting and treatment strategy. We performed a quasiexperimental noninferiority study comparing clinical outcomes of PCR+/CT-toxin- individuals by reporting PCR result only (most patients treated) with reporting CT-toxin result only (most patients untreated) in a single-center, tertiary academic hospital. The primary outcome was symptomatic PCR+/CT-toxin+ conversion at 8 weeks. Secondary outcomes included 7-day diarrhea resolution, hospital length of stay, and 30-day all-cause mortality. A total of 663 PCR+/CT-toxin- test results were analyzed from 632 individuals with a median age of 61 years (interquartile range [IQR], 44 to 72) and 50.4% immunocompromised. Individuals in the preintervention group were more likely to have received CDI therapy than those in the intervention group (91.5 versus 15.1%; P < 0.001). Symptomatic toxin conversion at 8 weeks and hospital length of stay failed to establish the predefined thresholds for noninferiority. Lack of diarrhea resolution at 7 days and 30-day all-cause mortality was similar and established noninferiority (20.0 versus 13.7%; adjusted odds ratio [aOR], 0.57; 90% confidence interval [CI], 0.32 to 1.01; P = 0.1; and 8.6 versus 6.5%; aOR, 0.46; 90% CI, 0.20 to 1.04; P = 0.12). These data support the safety of withholding antibiotics for selected hospitalized individuals with suspected CDI but negative toxin.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Hogan CA, Hitchcock MM, Frost S, et al. Clinical Outcomes of Treated and Untreated C. difficile PCR-Positive/Toxin-Negative Adult Hospitalized Patients: a Quasi-Experimental Noninferiority Study. J Clin Microbiol. 2022. PMID: 35611653. doi:10.1128/jcm.02187-21

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。